Abstract:Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic options of hepatobiliary malignancies. However, the clinical benefit provided by immunotherapy seems limited to a small subgroup of patients with hepatobiliary malignancies. The identification of reliable predictors of the response to immunotherapy is urgently needed. Data sources: Literature search was conducted in PubMed for relevant articles published up to May 2022. Information of clinical trials was obtained from https://clinicaltrials.gov/. Results: Biomarkers for ICI response of hepatobiliary malignancies remain in the exploration stage and lack compelling evidence. Tumor programmed death-ligand 1 (PD-L1) expression is the most widely studied biomarker in hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs), but there are conflicting results on its predictive potential. Tumor mutational burden (TMB) is generally low both in HCC and BTCs, and the clinical trials of TMB are rare in hepatobiliary malignancies. Promisingly, mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H) may be a predictive biomarker of response to anti-PD-1 therapy in BTCs. Furthermore, some emerging biomarkers, such as gut microbiota, show predictive potential in the preliminary studies. Radiomics and liquid-biopsy biomarkers, including circulating tumor cells, circulating tumor DNA (ctDNA) and exosomal PD-L1 provide a quick and non-invasive approach for monitoring the ICI response, showing a new promising direction. Conclusions: Multiple potential biomarkers for predicting ICI response of hepatobiliary malignancies have been explored and tried to apply in clinic. Yet there is no robust evidence to prove their clinical value in predicting immunotherapeutic response for patients with hepatobiliary malignancies. The identification of predictors for response to ICIs is an urgent need and major challenge. Further studies are warranted to validate the role of emerging biomarkers in predicting immunotherapeutic responses.

Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies

Heterogeneous Responses in Hepatocellular Carcinoma: the Achilles Heel of Immune Checkpoint Inhibitors.

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

Immune checkpoint inhibitor resistance in hepatocellular carcinoma

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Mechanism and strategies of immunotherapy resistance in colorectal cancer

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies

Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance

The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Biomarkers for response to immunotherapy in hepatobiliary malignancies

Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?

Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance

Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects

Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment

The Resistance Mechanisms of Lung Cancer Immunotherapy